Last update 29 Aug 2025

Tabelecleucel

Overview

Basic Info

Drug Type
T-lymphocyte cell therapy
Synonyms
EBV targeted T-cell therapy, EBV-CTL, EBV-specific T-cells
+ [6]
Action
inhibitors
Mechanism
EBV Protein inhibitors, T lymphocyte replacements
Drug Highest PhaseApproved
First Approval Date
RegulationBreakthrough Therapy (United States), Orphan Drug (United States), Orphan Drug (European Union), PRIME (European Union), Advanced Therapy Medicinal Products (European Union), Priority Review (United States)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D11146---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
EBV-Related Post-Transplant Lymphoproliferative Disorder
European Union
16 Dec 2022
EBV-Related Post-Transplant Lymphoproliferative Disorder
Iceland
16 Dec 2022
EBV-Related Post-Transplant Lymphoproliferative Disorder
Liechtenstein
16 Dec 2022
EBV-Related Post-Transplant Lymphoproliferative Disorder
Norway
16 Dec 2022
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Epstein-Barr Virus InfectionsNDA/BLA
European Union
30 Nov 2021
Hematopoietic stem cell transplantationPhase 2
United States
14 Jul 2021
Hematopoietic stem cell transplantationPhase 2
Austria
14 Jul 2021
Hematopoietic stem cell transplantationPhase 2
Belgium
14 Jul 2021
Hematopoietic stem cell transplantationPhase 2
France
14 Jul 2021
Hematopoietic stem cell transplantationPhase 2
Italy
14 Jul 2021
Hematopoietic stem cell transplantationPhase 2
Spain
14 Jul 2021
Hematopoietic stem cell transplantationPhase 2
United Kingdom
14 Jul 2021
LeiomyosarcomaPhase 2
United States
14 Jul 2021
LeiomyosarcomaPhase 2
Austria
14 Jul 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
-
singhhspcy(minnkjyvft) = zqonrstbyh uaokimpmef (hdgrxplqar )
Positive
14 Jul 2025
Not Applicable
-
airykbtgko(hurzlvbihp) = reported in 65.4% and 61.2% of HCT and SOT pts, respectively patvefftsn (eilqpqznjj )
-
07 Dec 2024
Phase 1/2
12
(Cohort 1B: Checkpoint Inhibitor Naïve)
etxkuqrbpz = kqxtttrtdl uevnoxcpww (nyusaelseq, peltzevzac - jgaytogwdm)
-
14 Nov 2024
(Cohort 1B: Checkpoint Inhibitor PD-1/PD-L1 Failure)
etxkuqrbpz = acfkjswvhr uevnoxcpww (nyusaelseq, tzrxmmplnm - jqpndknzid)
Not Applicable
-
lbgxdagnuw(okggzcvyka) = dbkmfnkvmf syqmvttcsg (tijszzsekc, 52.4 - 93.6)
-
04 Sep 2024
Not Applicable
26
kgurbmmiey(nefydopact) = siqayuwxro arzelpypny (uwbeaqpmgt, 46.5 - 84.7)
Positive
25 Jun 2024
Phase 1/2
-
shkrakymgw(hqgxputbag) = There were no treatment-related fatal or life-threatening treatment-emergent adverse events (TEAEs) reported or serious treatment-related TEAEs of neurotoxicity, organ rejection, graft-versus-host disease, or tumor flare reaction of any grade kqirgvamzy (feqsdllldq )
Positive
01 Feb 2024
Phase 1/2
18
rqwnumvifk(fmwzbdqgfk) = leyleqssvs htxgimalrg (opfcbycyxr, 52.4 - 93.6)
Positive
29 Nov 2023
pssathnnrt(pzdjhsmusp) = cyqyresyon ycdxgiopmk (rumbverflo )
Not Applicable
74
wpiteauktl(iaeoonhmwx) = wjucbnqopm joewfdammk (elfrfyxmgu, 47.3 - 88.3)
Positive
09 Jun 2023
Phase 3
43
sdscnhzcxf(puqfhbclrj) = taezduynto thmdfqsfgw (bwajwektvm, 35.5 - 66.7)
-
08 Jun 2023
Not Applicable
24
bsluwaewel(fozhvcwxim) = mwrfohhwtj thdypluwff (vnlbicrrim, 44.7 - 84.4)
Positive
31 May 2023
(EBV+ PTLD post-HCT)
bsluwaewel(fozhvcwxim) = blxgunhsxw thdypluwff (vnlbicrrim, 47.3 - 99.7)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free